Literature DB >> 39481

Pneumonia and pneumococcal infections, with special reference to pneumococcal pneumonia. The 1979 J. Burns Amberson lecture.

M Finland.   

Abstract

An etiologic classification of acute pneumonia was presented and the relative importance of some of the causative agents was briefly reviewed. The early developments of the therapy of pneumococcal pneumonia with type-specific antisera, sulfonamide drugs, and antimicrobial drugs were reviewed, mostly from the experiences of the author at Boston City Hospital. Changes in the occurrence and relative importance of the pneumococcus as a cause of infections associated with bacteremia, empyema, and meningitis were demonstrated, based on cases observed at Boston City Hospital during 12 selected years between 1935 and 1972. These findings, among others, indicate that the pneumococcus is still one of the most important causes of serious bacterial infections and of mortality from such infections, particularly in the elderly. Some possible indications for polyvalent pneumococcal capsular polysaccharide vaccine were discussed, and the need for further extensive clinical and field trials to demonstrate its range of effectiveness was stressed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 39481     DOI: 10.1164/arrd.1979.120.3.481

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  6 in total

1.  Bacampicillin treatment of pneumococcal pneumonia in high risk patients.

Authors:  S Campbell
Journal:  Bull N Y Acad Med       Date:  1983-06

Review 2.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

4.  Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia.

Authors:  M J Blaser; B D Klaus; J A Jacobson; E Kasworm; F M LaForce
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

5.  Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial.

Authors:  R J Wallace; R R Martin; F J Quinones; S B Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

6.  Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells.

Authors:  B Andersson; J Dahmén; T Frejd; H Leffler; G Magnusson; G Noori; C S Edén
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.